Statement: Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure.
Primary_evidence: Adverse Events 1:   Total: 56/199 (28.14%)   AGRANULOCYTOSIS 1/199 (0.50%)   ANAEMIA 1/199 (0.50%)   BONE MARROW FAILURE 1/199 (0.50%)   FEBRILE NEUTROPENIA 11/199 (5.53%)   LEUKOPENIA 1/199 (0.50%)   NEUTROPENIA 1/199 (0.50%)   PANCYTOPENIA 1/199 (0.50%)   ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%)   ATRIAL FLUTTER 1/199 (0.50%)   ATRIAL THROMBOSIS 0/199 (0.00%)   CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2:   Total: 66/198 (33.33%)   AGRANULOCYTOSIS 0/198 (0.00%)   ANAEMIA 0/198 (0.00%)   BONE MARROW FAILURE 0/198 (0.00%)   FEBRILE NEUTROPENIA 27/198 (13.64%)   LEUKOPENIA 0/198 (0.00%)   NEUTROPENIA 2/198 (1.01%)   PANCYTOPENIA 1/198 (0.51%)   ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%)   ATRIAL FLUTTER 0/198 (0.00%)   ATRIAL THROMBOSIS 1/198 (0.51%)   CARDIAC FAILURE 4/198 (2.02%)
Secondary_evidence: Adverse Events 1:   Total: 3/8 (37.50%)   Anaemia 0/8 (0.00%)   Febrile neutropenia 0/8 (0.00%)   Polycythaemia 0/8 (0.00%)   Acute coronary syndrome 0/8 (0.00%)   Vertigo 0/8 (0.00%)   Eyelid oedema 1/8 (12.50%)   Constipation 0/8 (0.00%)   Diarrhoea 0/8 (0.00%)   Nausea 0/8 (0.00%)   Stomatitis 0/8 (0.00%)   Upper gastrointestinal haemorrhage 0/8 (0.00%)   Vomiting 0/8 (0.00%)   Chest pain 0/8 (0.00%) Adverse Events 2:   Total: 2/6 (33.33%)   Anaemia 0/6 (0.00%)   Febrile neutropenia 0/6 (0.00%)   Polycythaemia 0/6 (0.00%)   Acute coronary syndrome 0/6 (0.00%)   Vertigo 0/6 (0.00%)   Eyelid oedema 0/6 (0.00%)   Constipation 0/6 (0.00%)   Diarrhoea 0/6 (0.00%)   Nausea 0/6 (0.00%)   Stomatitis 0/6 (0.00%)   Upper gastrointestinal haemorrhage 0/6 (0.00%)   Vomiting 0/6 (0.00%)   Chest pain 1/6 (16.67%)